4-HO-MiPT

4-HO-MiPT
Clinical data
Other names4-OH-MiPT; 4-Hydroxy-N-methyl-N-isopropyltryptamine; Miprocin
Routes of
administration
Oral
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • BR: Class F2 (Prohibited psychotropics)
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Unscheduled
Pharmacokinetic data
Onset of action10–20 minutes
Duration of action4–6 hours
Identifiers
  • 3-{2-[methyl(propan-2-yl)amino]ethyl}-1H-indol-4-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
Melting point123 to 125 °C (253 to 257 °F)
  • CN(C(C)C)CCC2=CNC1=CC=CC(O)=C12
  • InChI=1S/C14H20N2O/c1-10(2)16(3)8-7-11-9-15-12-5-4-6-13(17)14(11)12/h4-6,9-10,15,17H,7-8H2,1-3H3 checkY
  • Key:RXKGHZCQFXXWFQ-UHFFFAOYSA-N checkY
  (verify)

4-HO-MiPT, also known as 4-hydroxy-N-methyl-N-isopropyltryptamine or as miprocin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It appears to be similar to psilocin in terms of onset, duration, and effects. The drug is taken orally.

It acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. The drug is closely related structurally to MiPT, 4-HO-DiPT, and psilocin (4-HO-DMT).

4-HO-MiPT was first described in the literature by David Repke and colleagues in 1981. Its effects in humans were subsequently described by Repke and Alexander Shulgin in 1985 and 1997. The drug was first encountered as a novel designer drug by 2010.